BJS Open

Open Acces

Selective decontamination of the digestive tract in upper gastrointestinal surgery: systematic review with meta-analysis of randomized clinical trials

F. Scheufele^D, R. Schirren, H. Friess and D. Reim

Department of Surgery, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Ismaningerstrasse 22, D-81675 Munich, Germany *Correspondence to:* Dr D. Reim (e-mail: daniel.reim@tum.de)

Background: Infectious complications are common after gastrointestinal surgery. Selective decontamination of the digestive tract (SDD) might reduce their incidence. SDD is used widely in colorectal resections, but its role in upper gastrointestinal resection is less clear. The aim of this study was to investigate the impact of SDD on postoperative outcome in upper gastrointestinal surgery.

Methods: Studies investigating SDD in upper gastrointestinal surgery were included after search of medical databases (PubMed, Ovid, Cochrane Library and Google Scholar). Results were analysed according to predefined criteria. The incidence of perioperative overall complications and death was pooled. Risk of bias was assessed using the revised Cochrane risk-of-bias tool.

Results: Some 1384 studies were identified, of which four RCTs were included in the final analysis. These studies included 415 patients, of whom 213 (51·3 per cent) received standard treatment/placebo and 202 (48·7 per cent) had SDD. The incidence of anastomotic leakage (odds ratio (OR) 0·39, 95 per cent c.i. 0·19 to 0·80; P = 0.010) and pneumonia (OR 0·42, 0·23 to 0·78; P = 0.006) was reduced in patients receiving SDD. Rates of surgical-site infection (P = 0.750) and mortality (P = 0.130) were not affected by SDD.

Conclusion: SDD seems to be associated with reduction of anastomotic leakage and pneumonia following upper gastrointestinal resection, without affecting postoperative mortality.

Funding information German Society of Surgery (FORTÜNE programme)

Paper accepted 29 June 2020 Published online 4 August 2020 in Wiley Online Library (www.bjsopen.com). **DOI:** 10.1002/bjs5.50332

Introduction

Gastrointestinal surgery is frequently followed by infectious complications¹, which are associated with longer hospital stay and increased costs². Surgical-site infection (SSI) contributes up to 20 per cent of all hospital-acquired infections³. Several risk factors are known to be involved, including prolonged duration of surgery, low preoperative serum albumin level, high intraoperative blood loss, ASA grade, high BMI and perioperative hypothermia^{4–6}.

The gut microbiome appears to play a critical role in the development of postoperative infectious complications^{7,8}. For potentially contaminated surgical procedures, preoperative antibiotic prophylaxis with intraoperative repetition for longer procedures is considered to be the standard of care⁹. Preoperative decontamination of the digestive tract by intake of oral, commonly non-absorbable, antibiotics

can be added to this schedule. Selective decontamination of the digestive tract (SDD) is believed to target *Staphylococcus aureus*, yeast and pathogenic Gram-negative bacteria, representing risk factors for postoperative infection, and is continued until there is normal passage of stool and food intake^{10,11}.

In colorectal surgery¹², SDD in combination with mechanical bowel preparation is used widely, and a recent RCT¹³ demonstrated that SDD significantly reduced post-operative infectious complications. The situation is less clear regarding SDD in upper gastrointestinal surgery^{10,14}. The aim of this study was to conduct a systematic review and meta-analysis of the current evidence for the role of SDD, focusing on postoperative complications and mortality reported in RCTs in upper gastrointestinal surgery.

This study adhered to the PRISMA guidelines¹⁵ for performance of the meta-analysis.

Online medical databases (PubMed, Ovid, Cochrane Library and Google Scholar) were searched using a search term (Appendix S1, supporting information) and combinations of 'selective digestive decontamination', 'gastrointestinal surgery' and 'upper GI'. The last online database search was performed on 3 June 2019. Relevant articles specified in the reference list of identified articles were included. The studies included investigated SDD before upper gastrointestinal surgery, and only RCTs involving human subjects were considered. Only studies with at least an English abstract and published within the last 25 years were included. Those focusing on lower gastrointestinal surgery and SDD in the setting of transplantation were excluded. Inclusion of the selected studies was validated independently by three researchers. Data extraction and the assessment of quality and risk of bias across studies was performed independently by two researchers. In case of any differences, the subject was discussed until consensus was reached.

Postoperative complications (SSI, pneumonia, anastomotic insufficiency) were analysed as reported by the study authors within the time frames reported using authors' definitions of specific complications. Postoperative mortality was assessed as stated by the authors, including death during the hospital stay as well as within 30 days from surgery.

The study was registered in the PROSPERO database (registration number CRD42020144720).

Statistical analysis

Review Manager version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) was used to conduct the meta-analysis. Outcomes were encoded as dichotomous variables, and odds ratios (ORs) were calculated by assessing the incidence of respective outcomes. Study heterogeneity was assessed by estimating I^2 . Studies with an I^2 statistic above 33 per cent were considered to have high heterogeneity. Assuming random differences by chance in treatment procedure, patient characteristics and local differences, the Mantel-Haenszel statistical method was used with a random-effects model when I^2 was 33 per cent or above in the test for heterogeneity, and with a fixed-effect model when I^2 was less than 33 per cent. For statistical significance, a bilateral 95 per cent c.i. was defined. For the analysis of risk of bias, the revised Cochrane risk-of-bias tool for randomized trials (RoB 2) was employed. Funnel plots of included ORs were created using Review Manager version 5.3.

Results

The initial search resulted in 1384 studies investigating SDD in gastrointestinal surgery, of which four RCTs^{10,14,16,17} met the inclusion criteria and were included in the final analysis (*Fig. 1*). The studies included patients undergoing gastrectomy and oesophagectomy, mainly for malignant disease. A total of 415 patients were analysed, of whom 213 received standard-of-care treatment/placebo and 202 had SDD before surgery. Three of the four studies used polymyxin B, tobramycin and amphotericin B as SDD, four times daily with a cephalosporin as the perioperative intravenous antibiotic (*Table 1*). A study by Tetteroo and colleagues¹⁸ did not meet the inclusion criterion of publication within the last 25 years and was not included in the analysis.

Anastomotic leak

All 415 patients were eligible for the analysis of anastomotic insufficiency. This complication occurred in 28 of 213 patients (13.1 per cent) receiving standard-of-care treatment and in 12 of 202 (5.9 per cent) after SDD. SDD had a protective effect on anastomotic leakage (OR 0.39, 95 per cent c.i. 0.19 to 0.80; P = 0.010), and heterogeneity was low ($I^2 = 0$ per cent) (Fig. 2). In the study by Schardey and co-workers16, leak rates were reduced significantly in the SDD group (2.9 per cent versus 10.6 per cent in the control group; P = 0.049) (*Table 2*). In the Schardev study, anastomotic insufficiency was defined as a total intestinal wall defect at the suture line, diagnosed by a positive dye test or radiological contrast study. Riedel et al.17 found a reduction in anastomotic insufficiency by SDD of 16 versus 25 per cent, although no P value was given, nor was leakage defined. Farran and colleagues¹⁴ reported no influence of SDD on anastomotic insufficiency (2.5 versus 5.9 per cent; P = 0.405) (Table 2), which was diagnosed by oral administration of methylene blue, clinical leak through a wound or drains, or radiological contrast examination. Roos et al.¹⁰ reported a reduction in anastomotic insufficiency by SDD (12.5 per cent versus 23.3 per cent in the control group), but gave no Pvalue; they defined leakage using a combination of clinical presentation, blood results, and confirmation by CT or X-ray.

Pneumonia

The incidence of postoperative pneumonia in 324 eligible patients from three studies^{14,16,17} indicated that 42 of 170 (24.7 per cent) in the control group were affected compared with 19 of 154 (12.3 per cent) after SDD, giving

www.bjsopen.com

Fig. 1 PRISMA diagram for the review





Table 1 Details of selective decontamination for included RCTs									
		No. of patients			Perioperative		Regimen		
Reference	erence Year		SDD	Resection	antibiotics	SDD			
Schardey et al. ¹⁶	1997	103	102	Gastrectomy	Cefotaxime	Polymyxin B 100 mg, tobramycin 80 mg, amphotericin B 500 mg, vancomycin 125 mg	4 times daily, from 1 day before surgery to POD7		
Riedl et al. ²⁰	2001	16	12	Transthoracic resection of oesophagus and cardia	Cefazolin	Polymyxin B 100 mg, tobramycin 80 mg, amphotericin B 200 mg	4 times daily, from 4-7 days before surgery to POD7		
Farran et al. ¹⁷	2008	51	40	Gastrectomy, oesophagectomy	Amoxycillin/ clavulanic acid	Erythromycin 500 mg, gentamicin 80 mg, nystatin sulphate 100 mg	4 times daily, from 12 h before surgery to POD5		
Roos et al. ¹¹	2011	43	48	Oesophageal, gastric and hepatopancreatobiliary resections	Cefuroxime/ metronidazole	Polymyxin B 100 mg, tobramycin 80 mg, amphotericin B 500 mg	4 times daily, from 2 days before surgery until normal bowel function or minimum of POD3		

SDD, selective decontamination of the digestive tract; POD, postoperative day.

an OR of 0.42 (95 per cent c.i. 0.23 to 0.78; P = 0.006) in favour of SDD, with low heterogeneity ($I^2 = 0$ per cent) (*Fig. 3*). Schardey and colleagues¹⁶ demonstrated a significant reduction in pneumonia after SDD (8.8 per

cent versus 22.3 per cent in the control group; P = 0.012) (*Table 2*). Pneumonia was diagnosed when four of the following five criteria occurred: body temperature above 38.5°C, leucocyte count greater than 10^4 or less than

Fig. 2 Forest plot comparing anastomotic insufficiency following selective decontamination of the digestive tract versus standard treatment in upper gastrointestinal resections



A Mantel-Haenszel fixed-effect model was used for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. SDD, selective decontamination of the digestive tract.

Table 2 Outcomes of included studies				
Postoperative complication rate (%)*	Schardey et al. ¹⁶	Riedl et al. ¹⁷	Farran et al. ¹⁴	Roos et al. ¹⁰
Overall	30.4 versus 44.7	-	-	-
Р	0.049			
Pneumonia	8.8 versus 22.3	42 versus 56	12.5 versus 19.6	-
Р	0.012		0.269	
Anastomotic insufficiency	2.9 versus 10.6	16 versus 25	2.5 versus 5.9	12.5 versus 23.3
Р	0.049		0.405	
Surgical-site infection	4.9 versus 3.8	0 versus 0	-	33·3 versus 39·5
Р	1.000			
Mortality	4.9 versus 10.6	0 versus 6	5 versus 5.9	-
Р	0.100		0.615	

*Selective decontamination of the digestive tract (SDD) versus control group respectively.

 5×10^3 cells per µl, positive auscultation examination, lung infiltration on X-ray, or positive bacteriology. Riedl *et al.*¹⁷ found a reduction in postoperative pneumonia from 56 to 42 per cent with SDD, although no *P* value was given (*Table 2*); they used the definition of pneumonia from the Robert Koch Institute. Farran and colleagues¹⁴ reported no influence of SDD on postoperative pneumonia (12.5 *versus* 19.6 per cent; *P* = 0.269) (*Table 2*). Pneumonia was defined when two of the following characteristics were present: purulent respiratory secretion, fever, radiological infiltrates, rhonchi, positive auscultation of the chest, and positive bacteriology of respiratory secretions.

Surgical-site infection

SSI included wound infections as well as abscess formation, although definitions were inconsistent between the included studies. Of 324 patients, 21 of 162 (13.0 per cent) in the control group and 21 of 162 patients (13.0 per cent) in the SDD group were diagnosed as having an SSI (OR 0.89, 95 per cent c.i. 0.43 to 1.82; P = 0.750), with low heterogeneity ($I^2 = 0$ per cent) (*Fig. 4*). No individual study found a significant difference in SSI rates between control and SDD groups.

Mortality

Again, 324 patients were eligible for evaluation. Some 15 of 170 patients (8·8 per cent) died in the control group compared with seven of 154 (4·5 per cent) in the SDD group. Although there was a tendency in favour of SDD, significance was not reached (OR 0·50, 95 per cent c.i. 0·20 to 1·23; P = 0.130), with low heterogeneity ($I^2 = 0$ per cent) (*Fig. 5*). Of the three included studies, two^{14,16} found no improvement in mortality and one¹⁷ showed benefit for SDD (0 *versus* 6 per cent), but no *P* value was provided (*Table 2*).

www.bjsopen.com

	Pne	umonia	Weight (%)	Odds ratio				
Reference	SDD	Control			Odds ratio			
Farran et al.14	5 of 40	10 of 51	23.3	0.59 (0.18, 1.88)				
Riedl et al.17	5 of 12	9 of 16	13.6	0.56 (0.12, 2.53)				
Schardey et al.16	9 of 102	23 of 103	63·1	0.34 (0.15, 0.77)				
Total	19 of 154	42 of 170	100.0	0.42 (0.23, 0.78)		•		
Heterogeneity: $\chi^2 = 0$)·72, 2 d.f., P=0	0·70; <i>l</i> ² =0%						

ative provimonia following selective decontamination of the digestive tract versus sta

A Mantel-Haenszel fixed-effect model was used for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. SDD, selective decontamination of the digestive tract.

Fig. 4 Forest plot comparing surgical-site infection following selective decontamination of the digestive tract versus standard treatment in upper gastrointestinal resections

	Surgical-site infection								
Reference	SDD	Control	Weight (%)	Odds ratio		Odds ratio			
Riedl et al.17	0 of 12	0 of 16		Not estimable					
Roos et al.10	16 of 48	17 of 43	76.0	0.76 (0.32, 1.80)					
Schardey et al.16	5 of 102	4 of 103	24.0	1.28 (0.33, 4.89)					
Total	21 of 162	21 of 162	100.0	0.89 (0.43, 1.82)					
Heterogeneity: $\chi^2 = 0$	0·40, 1 d.f., P=	0·53; <i>I</i> ²=0%							
Test for overall effect: $Z=0.32$, $P=0.75$					0.01	0.1	1	10	100
					Favours SDD Favours control				

A Mantel-Haenszel fixed-effect model was used for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. SDD, selective decontamination of the digestive tract.



A Mantel-Haenszel fixed-effect model was used for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. SDD, selective decontamination of the digestive tract.

Publication bias

Funnel plots showed even distribution within the pseudo 95 per cent c.i., suggesting no publication bias for incidence of anastomotic insufficiency, pneumonia, SSI or mortality (*Fig. S1*, supporting information). Analysis using the Cochrane risk-of-bias tool (RoB 2) for randomized trials revealed 'some concerns' in the randomization process and deviations from intended interventions in the study by Riedl and colleagues¹⁷. The other included studies^{10,14,16} had a low risk of bias (*Fig. S2*, supporting information).

Discussion

This meta-analysis has demonstrated a reduction in anastomotic leakage and postoperative pneumonia after SDD for upper gastrointestinal surgery. Anastomotic leak was not defined uniformly, but adhered to a common basis. Three of the four studies identified a reduction in leak rates, and two of the three included studies showed a reduction in pneumonia, although in these two studies there was a threefold to fourfold difference in the prevalence of pneumonia, probably reflecting differences in definition.

In the study by Schardey *et al.*¹⁶, which used tobramycin, polymyxin B, amphotericin B and vancomycin for SDD, a concurrent effect of reduced bacterial oropharyngeal colonization was found¹⁹. This might relate to the reduced incidence of pneumonia, as microaspiration is associated with postoperative pneumonia²⁰.

The number of eligible RCTs for this analysis was low, limiting its conclusions. An RCT by Tetteroo and colleagues¹⁸ had different reporting of complications and was outdated and thus not included in the analysis. Overall morbidity was reported in only one study¹⁶. The type of resection varied, although most of the included patients underwent oesophagectomy or gastrectomy. The studies cover the time period for the introduction of minimal-access approaches in upper gastrointestinal surgery. These operations are associated with a reduced risk of postoperative infectious morbidity. Of the included studies, only Roos and co-workers¹⁰ reported on the use of minimally invasive surgery, although the percentage of a specific procedure (e.g. gastric resection) was not apparent. Conversely, increasingly aggressive therapies for upper gastrointestinal cancers expose patients to increased risk of infection²¹.

In this analysis, three of the four included studies were underpowered with regard to their primary endpoint. Only the study of Roos *et al.*¹⁰ was of sufficient size for analysis of infectious complications. Based on the metadata, analysis of anastomotic leakage would need 548 patients (13 per cent placebo *versus* 6 per cent SDD), pneumonia 278 patients (25 versus 12 per cent) and mortality 1276 patients (9 versus 5 per cent) to reach a power of 80 per cent with an α error of 5 per cent. As detrimental side-effects and selection of resistant bacteria by SDD are uncommon, further well designed RCTs should investigate the impact of SDD in upper gastrointestinal surgery²². Hepatopancreatobiliary resections would be of particular interest, as preoperative biliary stenting is a known risk factor for postoperative infectious complications⁸.

Acknowledgements

F.S. was funded by a German Society of Surgery scholarship (FORTÜNE programme) with D.R. as a mentor. *Disclosure:* The authors declare no conflict of interest.

References

- Vazquez-Aragon P, Lizan-Garcia M, Cascales-Sanchez P, Villar-Canovas MT, Garcia-Olmo D. Nosocomial infection and related risk factors in a general surgery service: a prospective study. *7 Infect* 2003; 46: 17–22.
- 2 Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. *Infect Control Hosp Epidemiol* 1999; 20: 725–730.
- 3 Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. *J Hosp Infect* 2017; 96: 1–15.
- 4 Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1999; 20: 250–278.
- 5 Pikarsky AJ, Saida Y, Yamaguchi T, Martinez S, Chen W, Weiss EG *et al.* Is obesity a high-risk factor for laparoscopic colorectal surgery? *Surg Endosc* 2002; **16**: 855–858.
- 6 Hedrick TL, Turrentine FE, Smith RL, McElearney ST, Evans HL, Pruett TL *et al*. Single-institutional experience with the surgical infection prevention project in intra-abdominal surgery. *Surg Infect (Larchmt)* 2007; **8**: 425–436.
- 7 Alverdy JC, Hyoju SK, Weigerinck M, Gilbert JA. The gut microbiome and the mechanism of surgical infection. *Br J Surg* 2017; **104**: e14–e23.
- 8 Scheufele F, Aichinger L, Jäger C, Demir IE, Schorn S, Sargut M *et al.* Effect of preoperative biliary drainage on bacterial flora in bile of patients with periampullary cancer. *Br 7 Surg* 2017; **104**: e182–e188.
- 9 Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. *Cochrane Database Syst Rev* 2014; (5)CD001181.
- 10 Roos D, Dijksman LM, Oudemans-van Straaten HM, de Wit LT, Gouma DJ, Gerhards MF. Randomized clinical trial of perioperative selective decontamination of the digestive

www.bjsopen.com

tract *versus* placebo in elective gastrointestinal surgery. *Br J Surg* 2011; **98**: 1365–1372.

- 11 Zandstra DF, Van Saene HKF. Selective decontamination of the digestive tract as infection prevention in the critically ill. A level 1 evidence-based strategy. *Minerva Anestesiol* 2011; 77: 212–219.
- 12 Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N *et al.* Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS[®]) Society recommendations: 2018. *World J Surg* 2019; **43**: 659–695.
- 13 Abis GSA, Stockmann HBAC, Bonjer HJ, van Veenendaal N, van Doorn-Schepens MLM, Budding AE *et al.*; SELECT trial study group. Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial). *Br J Surg* 2019; 106: 355–363.
- 14 Farran L, Llop J, Sans M, Kreisler E, Miró M, Galan M et al. Efficacy of enteral decontamination in the prevention of anastomotic dehiscence and pulmonary infection in esophagogastric surgery. *Dis Esophagus* 2008; 21: 159–164.
- 15 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6: e1000097.
- 16 Schardey HM, Joosten U, Finke U, Staubach KH, Schauer R, Heiss A. The prevention of anastomotic leakage after total gastrectomy with local decontamination. A

prospective, randomized, double-blind, placebo-controlled multicenter trial. *Ann Surg* 1997; **225**: 172–180.

- 17 Riedl S, Peter B, Geiss HK, Aulmann M, Bach A, Lehnert T. Microbiological and clinical effects of selective bowel decontamination in transthoracic resection of carcinoma of the esophagus and cardia. *Chirurg* 2001; 72: 1160–1170.
- 18 Tetteroo GWM, Wagenvoort JH, Castelein A, Tilanus HW, Ince C, Bruining HA. Selective decontamination to reduce Gram-negative colonisation and infections after oesophageal resection. *Lancet* 1990; **335**: 704–707.
- 19 Schardey HM, Kamps T, Rau HG, Gatermann S, Baretton G, Schildberg FW. Bacteria: a major pathogenic factor for anastomotic insufficiency. *Antimicrob Agents Chemother* 1994; 38: 2564–2567.
- 20 D'Haese J, de Keukeleire T, Remory I, van Rompaey K, Umbrain V, Poelaert J. Assessment of intraoperative microaspiration: does a modified cuff shape improve sealing? *Acta Anaesthesiol Scand* 2013; 57: 873–880.
- 21 Cools KS, Sanoff HK, Kim HJ, Yeh JJ, Stitzenberg KB. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. *J Surg Oncol* 2018; **118**: 455–462.
- 22 Daneman N, Sarwar S, Fowler RA, Cuthbertson BH; SuDDICU Canadian Study Group. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. *Lancet Infect Dis* 2013; **13**: 328–341.

Supporting information

Additional supporting information can be found online in the Supporting Information section at the end of the article.